Fusion Pharmaceuticals Competitors

Fusion Pharmaceuticals (NASDAQ:FUSN) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, earnings and dividends.

Institutional & Insider Ownership

61.4% of Fusion Pharmaceuticals shares are owned by institutional investors. Comparatively, 57.7% of Sangamo Therapeutics shares are owned by institutional investors. 1.8% of Sangamo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Fusion Pharmaceuticals and Sangamo Therapeutics' revenue, earnings per share and valuation.

Fusion Pharmaceuticals has higher earnings, but lower revenue than Sangamo Therapeutics.

Analyst Recommendations

This is a summary of recent recommendations for Fusion Pharmaceuticals and Sangamo Therapeutics, as reported by MarketBeat.

Fusion Pharmaceuticals currently has a consensus price target of $23.6667, indicating a potential upside of 148.86%. Sangamo Therapeutics has a consensus price target of $20.20, indicating a potential upside of 83.30%. Given Fusion Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Fusion Pharmaceuticals is more favorable than Sangamo Therapeutics.

Profitability

This table compares Fusion Pharmaceuticals and Sangamo Therapeutics' net margins, return on equity and return on assets.

Summary

Fusion Pharmaceuticals beats Sangamo Therapeutics on 6 of the 10 factors compared between the two stocks.

Fusion Pharmaceuticals (NASDAQ:FUSN) and Krystal Biotech (NASDAQ:KRYS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, earnings and dividends.

Institutional & Insider Ownership

61.4% of Fusion Pharmaceuticals shares are owned by institutional investors. Comparatively, 73.1% of Krystal Biotech shares are owned by institutional investors. 27.4% of Krystal Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Fusion Pharmaceuticals and Krystal Biotech's revenue, earnings per share and valuation.

Analyst Recommendations

This is a summary of recent recommendations for Fusion Pharmaceuticals and Krystal Biotech, as reported by MarketBeat.

Fusion Pharmaceuticals currently has a consensus price target of $23.6667, indicating a potential upside of 148.86%. Krystal Biotech has a consensus price target of $101.00, indicating a potential upside of 45.76%. Given Fusion Pharmaceuticals' higher probable upside, equities analysts clearly believe Fusion Pharmaceuticals is more favorable than Krystal Biotech.

Profitability

This table compares Fusion Pharmaceuticals and Krystal Biotech's net margins, return on equity and return on assets.

Summary

Krystal Biotech beats Fusion Pharmaceuticals on 5 of the 7 factors compared between the two stocks.

Fusion Pharmaceuticals (NASDAQ:FUSN) and Immunovant (NASDAQ:IMVT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, earnings and dividends.

Institutional & Insider Ownership

61.4% of Fusion Pharmaceuticals shares are owned by institutional investors. Comparatively, 40.2% of Immunovant shares are owned by institutional investors. 0.2% of Immunovant shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Fusion Pharmaceuticals and Immunovant's revenue, earnings per share and valuation.

Analyst Recommendations

This is a summary of recent recommendations for Fusion Pharmaceuticals and Immunovant, as reported by MarketBeat.

Fusion Pharmaceuticals currently has a consensus price target of $23.6667, indicating a potential upside of 148.86%. Immunovant has a consensus price target of $45.60, indicating a potential upside of 190.82%. Given Immunovant's higher probable upside, analysts clearly believe Immunovant is more favorable than Fusion Pharmaceuticals.

Profitability

This table compares Fusion Pharmaceuticals and Immunovant's net margins, return on equity and return on assets.

Summary

Fusion Pharmaceuticals beats Immunovant on 5 of the 8 factors compared between the two stocks.

Fusion Pharmaceuticals (NASDAQ:FUSN) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, earnings and dividends.

Institutional & Insider Ownership

61.4% of Fusion Pharmaceuticals shares are owned by institutional investors. Comparatively, 32.1% of AlloVir shares are owned by institutional investors. 1.0% of AlloVir shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Fusion Pharmaceuticals and AlloVir's revenue, earnings per share and valuation.

Analyst Recommendations

This is a summary of recent recommendations for Fusion Pharmaceuticals and AlloVir, as reported by MarketBeat.

Fusion Pharmaceuticals currently has a consensus price target of $23.6667, indicating a potential upside of 148.86%. AlloVir has a consensus price target of $48.75, indicating a potential upside of 110.04%. Given Fusion Pharmaceuticals' higher probable upside, equities analysts clearly believe Fusion Pharmaceuticals is more favorable than AlloVir.

Profitability

This table compares Fusion Pharmaceuticals and AlloVir's net margins, return on equity and return on assets.

Fusion Pharmaceuticals (NASDAQ:FUSN) and Kymera Therapeutics (NASDAQ:KYMR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, earnings and dividends.

Institutional & Insider Ownership

61.4% of Fusion Pharmaceuticals shares are owned by institutional investors. Comparatively, 37.8% of Kymera Therapeutics shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Fusion Pharmaceuticals and Kymera Therapeutics' revenue, earnings per share and valuation.

Analyst Recommendations

This is a summary of recent recommendations for Fusion Pharmaceuticals and Kymera Therapeutics, as reported by MarketBeat.

Fusion Pharmaceuticals currently has a consensus price target of $23.6667, indicating a potential upside of 148.86%. Kymera Therapeutics has a consensus price target of $48.6667, indicating a potential upside of 45.53%. Given Fusion Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Fusion Pharmaceuticals is more favorable than Kymera Therapeutics.

Profitability

This table compares Fusion Pharmaceuticals and Kymera Therapeutics' net margins, return on equity and return on assets.

Summary

Fusion Pharmaceuticals beats Kymera Therapeutics on 4 of the 6 factors compared between the two stocks.

Fusion Pharmaceuticals (NASDAQ:FUSN) and REGENXBIO (NASDAQ:RGNX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, earnings and dividends.

Institutional & Insider Ownership

61.4% of Fusion Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.2% of REGENXBIO shares are owned by institutional investors. 14.1% of REGENXBIO shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Fusion Pharmaceuticals and REGENXBIO's revenue, earnings per share and valuation.

Fusion Pharmaceuticals has higher earnings, but lower revenue than REGENXBIO.

Analyst Recommendations

This is a summary of recent recommendations for Fusion Pharmaceuticals and REGENXBIO, as reported by MarketBeat.

Fusion Pharmaceuticals currently has a consensus price target of $23.6667, indicating a potential upside of 148.86%. REGENXBIO has a consensus price target of $62.50, indicating a potential upside of 77.71%. Given Fusion Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Fusion Pharmaceuticals is more favorable than REGENXBIO.

Profitability

This table compares Fusion Pharmaceuticals and REGENXBIO's net margins, return on equity and return on assets.